Articles

A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment.

The Academy of Oncology Nurse & Patient Navigators^® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeons Commission on Cancer (CoC).

In his NCCN update of the CLL guideline, Dr Wierda noted that the Bruton’s tyrosine kinase (BTK) inhibitor­ ibrutinib (Imbruvica) could soon replace conventional chemotherapy.

In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication.

With the exception of skin cancer, prostate cancer is the most common cancer affecting men.

“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime.”

Section 529 college savings plans are tax-advantaged college savings vehicles, and one of the most popular ways to save for college today.

Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the National Comprehensive Cancer Network 20th Annual Conference, the newer drug, pazopanib, may have some benefit in total cost of care; survival outcomes were the same between drugs.

Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy As­­sociation conference.

Dr Papadopoulou and colleagues conducted a study evaluating treatment and prevention of medication associated ONJ, and presented their findings.